We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCIR
RNS Number : 7826S
Circassia Pharmaceuticals Plc
27 June 2018
27 JUNE 2018
CIRCASSIA PHARMACEUTICALS PLC
PUBLICATION OF CIRCULAR
On 24 April 2018, Circassia Pharmaceuticals plc (the Company) announced that, conditional on the approval of the Company's shareholders, it had agreed to amend certain terms of its development and commercialisation agreement (DCA) with AstraZeneca dated 17 March 2017 and to issue further shares to AstraZeneca in connection therewith (the Transaction).
The Company today announces the publication of a circular (the Circular) containing a notice of general meeting of the Company's shareholders to be convened at 12.00 on 16 July 2018 at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom (the General Meeting). At the General Meeting, the Company's independent shareholders will be asked to approve a special resolution to authorise the Transaction as a "related party transaction" under the Listing Rules. The procedures and timings for shareholders to vote on the special resolution are set out in the notice of the General Meeting in the Circular.
The Circular also includes an update on the Company's free float status and related undertakings to the FCA under the Listing Rules, including the potential move of the Company's listing to AIM. Further background and details regarding this matter are set out on pages 8 and 9 of the Circular.
The Circular and a Form of Proxy in relation to the General Meeting are being posted today, and the Circular will shortly be available for viewing, subject to regulatory requirements, on the Company's website at www.circassia.com/investors/. A copy of the Circular will also be submitted to the National Storage Mechanism and will shortly be available at www.morningstar.co.uk/uk/NSM.
For further information, please contact:
Circassia Steve Harris, Chief Executive Tel: +44 (0) 1865 405 560 Officer Julien Cotta, Chief Financial Officer Rob Budge, Corporate Communications JP Morgan Cazenove James Mitford / James Deal Tel: +44 (0) 20 7742 4000 Numis Securities Clare Terlouw / Freddie Barnfield Tel: +44 (0) 20 7260 1000 FTI Consulting Simon Conway / Mo Noonan Tel: +44 (0) 20 3727 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CIRLLFFLRIIDFIT
(END) Dow Jones Newswires
June 27, 2018 07:23 ET (11:23 GMT)
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
